GFAT1 Antibody (D-9): sc-377479

GFAT1 Antibody (D-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects GFAT1 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). GFAT1 (D-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Glutamine:fructose-6-phosphate amidotransferase (GFAT1) plays a crucial role as the first and rate-limiting enzyme in the hexosamine biosynthesis pathway, which is essential for the synthesis of glycoproteins and glycolipids that are vital for cellular functions. GFAT1 is primarily located in the cytoplasm, where GFAT1 catalyzes the conversion of fructose-6-phosphate into N-acetylglucosamine-6-phosphate, a precursor for the production of UDP-N-acetylglucosamine. This process links glucose metabolism to the regulation of cellular signaling pathways and gene expression, influencing various physiological processes. Dysregulation of GFAT1 activity has been implicated in metabolic disorders, including hyperglycemia-induced insulin resistance, which is a hallmark of type 2 diabetes. GFAT1 serves as not only a critical enzyme in metabolic pathways but also a potential therapeutic target for managing type 2 diabetes and related conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

GFAT1 Antibody (D-9) References:

1. Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress.  |  Kaneto, H., et al. 2001. J Biol Chem. 276: 31099-104. PMID: 11390407
2. Identification of GFAT1-L, a novel splice variant of human glutamine: fructose-6-phosphate amidotransferase (GFAT1) that is expressed abundantly in skeletal muscle.  |  Niimi, M., et al. 2001. J Hum Genet. 46: 566-71. PMID: 11587069
3. A novel variant of glutamine: fructose-6-phosphate amidotransferase-1 (GFAT1) mRNA is selectively expressed in striated muscle.  |  DeHaven, JE., et al. 2001. Diabetes. 50: 2419-24. PMID: 11679416
4. Kinetic characterization of human glutamine-fructose-6-phosphate amidotransferase I: potent feedback inhibition by glucosamine 6-phosphate.  |  Broschat, KO., et al. 2002. J Biol Chem. 277: 14764-70. PMID: 11842094
5. A radiometric assay for glutamine:fructose-6-phosphate amidotransferase.  |  Broschat, KO., et al. 2002. Anal Biochem. 305: 10-5. PMID: 12018941
6. Molecular screening of the human glutamine-fructose-6-phosphate amidotransferase 1 (GFPT1) gene and association studies with diabetes and diabetic nephropathy.  |  Elbein, SC., et al. 2004. Mol Genet Metab. 82: 321-8. PMID: 15308130
7. Molecular therapeutic target for type-2 diabetes.  |  Chou, KC. 2004. J Proteome Res. 3: 1284-8. PMID: 15595739
8. Partial characterisation of the human GFAT promoter: effect of single nucleotide polymorphisms on promoter function.  |  Burt, D., et al. 2005. Biochim Biophys Acta. 1740: 85-90. PMID: 15878746
9. High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer.  |  Yang, C., et al. 2016. Sci Rep. 6: 39044. PMID: 27996048
10. Loss of GFAT-1 feedback regulation activates the hexosamine pathway that modulates protein homeostasis.  |  Ruegenberg, S., et al. 2020. Nat Commun. 11: 687. PMID: 32019926
11. Critical Role of Preoperative Hyperglycemia in Association with GFAT-1 Expression in Resected Pancreatic Cancer.  |  Kohara, Y., et al. 2024. Ann Surg Oncol. 31: 7713-7721. PMID: 39107610
12. Expression of glutamine:fructose-6-phosphate amidotransferase in human tissues: evidence for high variability and distinct regulation in diabetes.  |  Nerlich, AG., et al. 1998. Diabetes. 47: 170-8. PMID: 9519709

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-GFAT1 Antibody (D-9) has 6 citations in a variety of scientific publications.

Primary antibodies like Anti-GFAT1 Antibody (D-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

GFAT1 Antibody (D-9) Specifications

Alternate Product Name: GFAT1

Product Clone Name: D-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 226-274

Epitope Target: GFAT1

Epitope Species: human

Product Reactivity/Detection: GFAT1

Species Reactivity/Detection: human

Additional Mammalian Reactivity: canine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 6 citations in various scientific publications

Available Conjugates/Forms for GFAT1 Antibody (D-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin